ProCE Banner Activity

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

Events

Share

Provided by

ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.